Aug 21, 2024 / NTS GMT
Ziyi Chen - Goldman Sachs - Analyst
Good morning, and good evening, global investors. Thank you for joining WuXi Biologics first-half 2024 interim results earnings call. This is Lai Chen, China health care analyst at Goldman Sachs.
Before we kick off the session, I would like to highlight that this call is strictly for clients of Goldman Sachs and WuXi Biologics only, and this conversation is not intended for media and is off the record. Participants will be removed on the call if they cannot be properly identified. And this call is not for the purpose of sharing or receiving them public or otherwise confidential information. Attendees are public side market participants who may not receive and should not request nonpublic or otherwise confidential information about issuers or securities or about markets of securities.
Today, we are honored to have Dr. Chris Chen, our CEO of the company; Dr. Ming Tu, CFO of the company; and also Dr. Lina Fan, Head of IR, joining the call to give us a briefing on the first half results and also the outlook.
Without further ado, I'm going to turn the
Half Year 2024 WuXi Biologics (Cayman) Inc Earnings Call Transcript
Aug 21, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers